Soluble mesothelin, a cell surface glycoprotein predominant in several types of cancer, is an independent prognostic marker and a new potential therapeutic target for patients…

Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and…

Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will…

Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda…

A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy.…

Malignant Pleural Mesothelioma So, what is mesothelioma? Malignant pleural mesothelioma is a very aggressive and almost always fatal type of cancer caused by exposure to Asbestos.…

A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…

It is safe for malignant mesothelioma patients to combine Tremelimumab and Imfinzi (durvalumab), according to a study to be presented at the 2017 American Society of Clinical…